Farallon Capital Management Adds Sycamore Networks Inc. (SCMR) To Its Equity Portfolio
Farallon Capital Management, in latest filing, disclosed that it initiated a position in Sycamore Networks, Inc.
Posts Tagged ‘Onyx Pharmaceuticals Inc (ONXX)’
An Excellent Investment in the Biotech Space?
According to the American Cancer Society, more than 60,000 new cases of thyroid cancer will be diagnosed in the U.S., and about 1,850 people are expected to die from the disease...
Celgene Corporation (CELG), Onyx Pharmaceuticals, Inc. (ONXX): Revelations From This Blazing Biotech
With all of the heat generated by this biotech and its stock, it pays to pay attention to what Celgene Corporation (NASDAQ:CELG) says.
Do Hedge Funds and Insiders Love Seattle Genetics, Inc. (SGEN)?
At the moment, there are a multitude of metrics shareholders can use to monitor stocks. A pair of the most useful are hedge fund and insider trading sentiment.
Celgene Corporation (CELG), Onyx Pharmaceuticals, Inc. (ONXX), Johnson & Johnson (JNJ): When Will the Good News End for This Biotech?
The big biotech announced on Thursday that updated results from its phase 3 study of Pomalyst in treating relapsed or refractory multiple myeloma had been published online in ...
Astex Pharmaceuticals, Inc. (ASTX) Becomes the Latest Biotech Domino to Fall
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) is being scooped up by Tokyo-based Otsuka Pharmaceuticals.
Amgen, Inc. (AMGN), Astex Pharmaceuticals, Inc. (ASTX), Pharmacyclics, Inc. (PCYC): This Week in Biotech
With the SPDR S&P Biotech Index up 35% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Amgen, Inc. (AMGN), Onyx Pharmaceuticals, Inc. (ONXX): Monday’s Best Stocks
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Amgen, Inc. (AMGN), Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Onyx Pharmaceuticals, Inc. (ONXX): This Biotech Envisions Green
After a second offer, Amgen, Inc. (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc.
The Amgen, Inc. (AMGN)-Onyx Pharmaceuticals, Inc. (ONXX) Deal Should Make All Biotech Investors Happy
While that's certainly not what Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) investors were hoping for -- at one point, after Amgen, Inc.
Amgen, Inc. (AMGN), Onyx Pharmaceuticals, Inc. (ONXX), NASDAQ OMX Group, Inc. (NDAQ): Deals, Not Data, Drive Dow Today
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Amgen, Inc. (AMGN) and Onyx Pharmaceuticals, Inc. (ONXX): Half a Billion Dollars’ Worth of Drama
A finale has at last arrived for the biotech drama of summer 2013. Amgen, Inc. (NASDAQ:AMGN) announced yesterday that it will buy Onyx Pharmaceuticals, Inc.
What Hedge Funds Think About Vertex Pharmaceuticals Incorporated (VRTX)
In the 21st century investor’s toolkit, there are tons of metrics market participants can use to track the equity markets.
What Is Amgen, Inc. (AMGN) Getting For Its Money?
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Onyx Pharmaceuticals, Inc. (ONXX) Investors: Listen Up
In the 21st century investor’s toolkit, there are tons of metrics shareholders can use to track publicly traded companies.
Hedge Funds Are Crazy About BioMarin Pharmaceutical Inc. (BMRN)
In the financial world, there are dozens of gauges shareholders can use to analyze stocks. Two of the most under-the-radar are hedge fund and insider trading sentiment.
Amgen, Inc. (AMGN), AstraZeneca plc (ADR) (AZN): What’s the Big Deal About Onyx Pharmaceuticals, Inc. (ONXX) Anyway?
At the end of June, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) announced that it had rejected an offer from Amgen, Inc.
Is Illumina, Inc. (ILMN) Going to Burn These Hedge Funds?
If you were to ask many investors, hedge funds are assumed to be useless, old investment tools of a period lost to current times.
Medivation Inc (MDVN), Seattle Genetics, Inc. (SGEN) – Biotech Buyouts: Who’s Next?
There's been plenty of buzz lately about the continuing saga of the possible buyout of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) by Amgen, Inc. (NASDAQ:AMGN).
Onyx Pharmaceuticals, Inc. (ONXX), Johnson & Johnson (JNJ): Celgene Corporation (CELG)’s Multiple Myeloma Powerhouse
Earlier this month, biotech powerhouse Celgene Corporation (NASDAQ:CELG) announced that the European Commission approved the combinational therapy of pomalidomide, known in the...
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN), Alexion Pharmaceuticals, Inc. (ALXN): Biotech’s Falling Fortunes Stymie Osiris Therapeutics, Inc. (OSIR)’s Huge Week
Biotech's the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts...
Incyte Corporation (INCY), BioMarin Pharmaceutical Inc. (BMRN): Two Biotech Stocks That Could Be on Novartis AG (ADR) (NVS)’s Buyout Radar
The buyout drama surrounding cancer drug maker Onyx Pharmaceuticals, Inc.
Celgene Corporation (CELG), Compugen Ltd. (USA) (CGEN): This Week in Biotech
With the SPDR S&P Biotech Index up 40% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Amgen, Inc. (AMGN), Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): A Closer Look at the Battle Over Cancer Treatments
Over the past year, the battle over cancer treatments has heated up considerably. Big pharma companies such as Amgen, Inc. (NASDAQ:AMGN), Pfizer Inc.
Alexion Pharmaceuticals, Inc. (ALXN), Onyx Pharmaceuticals, Inc. (ONXX): Will This Orphan Drug Maker Find a New Home?
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), already quite expensive, spiked higher since takeover rumors surfaced in early July.
Alexion Pharmaceuticals, Inc. (ALXN), Onyx Pharmaceuticals, Inc. (ONXX): This Orphan Drug Company Only Appears Expensive
In the last couple of months, we saw two big offers being made - and rejected - in the biotech sector.
Celgene Corporation (CELG): Has Multiple Myeloma Met its Match?
Multiple myeloma is a cancer of plasma cells, a type of white blood cell present in bone marrow.
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN): Will This Biotech Bidding War Lead You to Larger Gains?
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) added 3% to its one-month 60% gains on Monday because of continued speculation of a buyout.
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN): Why Getting Rich Quick Doesn’t (Always) Pay
We have a bona fide biotech soap opera going on these days. Spurned love. Possible romance. Disgruntled suitor. And, of course, the unknown villain.
Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ), Onyx Pharmaceuticals, Inc. (ONXX), Seattle Genetics, Inc. (SGEN): Betting on Blockbusters
Global biotechnology industry revenue is expected to reach $262 billion this year showing growth of around 12.7% year over year.
Amgen, Inc. (AMGN)’s Acquisition Ambition Leads Biotechs’ Rise
Biotech's the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts...
Celgene Corporation (CELG): Expanding Labels to Expand Margins
In an industry where buyouts are commonplace and small-cap biotechs burn through cash rapidly, optimizing operating cash flow can be essential to a company's financial health.
Four Potential Suitors for Onyx Pharmaceuticals, Inc. (ONXX)
The "people familiar with the matter" are out in full force spouting off about who's bidding for Onyx Pharmaceuticals, Inc.
Celgene Corporation (CELG): Can This Biotech Go Even Higher?
Celgene Corporation (NASDAQ:CELG) has emerged as the leading treatment provider for blood cancer.
Celgene Corporation (CELG), Onyx Pharmaceuticals, Inc. (ONXX): A Fundamentally Strong Biotech Stock
Celgene Corporation (NASDAQ:CELG) surged 7% on Thursday, July 11, 2013 on news that the Phase III trials of Revlimid /dexamethasone combination showed that it could be an initial...
Is Pfizer Inc. (PFE) Destined for Greatness?
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown.
Onyx Pharmaceuticals, Inc. (ONXX), Alexion Pharmaceuticals, Inc. (ALXN): 3 Biotechs That Could Be Bought Out This Year
Chances are that a few biotech companies will be scooped up by larger players over the coming months.
Revlimid Results Rev Up Celgene Corporation (CELG)
Good news seems to find its way to Celgene Corporation (NASDAQ:CELG)'s door frequently these days.
Who Could Buy Onyx Pharmaceuticals, Inc. (ONXX) and at What Price?
Recently Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) rejected a $10 billion takeover offer from Amgen, Inc. (NASDAQ:AMGN).
Who Is the Best Suitor for Onyx Pharmaceuticals, Inc. (ONXX)?
Cancer-drug maker Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) recently rejected an $8.7 billion unsolicited acquisition offer from Amgen, Inc. (NASDAQ:AMGN).
Onyx Pharmaceuticals, Inc. (ONXX), Pharmacyclics, Inc. (PCYC): Will This Biotech Acquisition Buzz Lead to More Buyouts?
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is trading higher after rejecting a takeover bid.
Amgen, Inc. (AMGN) Stirs the Pot in the Cancer-Related Sector
Several companies are fighting to be the first to release a treatment or cure for cancer that is a game-changer, and this battle has created a field where firms are looking to...
Onyx Pharmaceuticals, Inc. (ONXX), Achillion Pharmaceuticals, Inc. (ACHN): This Week in Biotech
With the SPDR S&P Biotech Index up 20% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Onyx Pharmaceuticals, Inc. (ONXX), Celldex Therapeutics, Inc. (CLDX): Three Humongous Health-Care Stocks This Week
While many American skies were lit up with fireworks this week, the stock market also saw its share of pops, sizzles, and bangs.
How Much Is Onyx Pharmaceuticals, Inc. (ONXX) Really Worth?
The promising cancer developer confirmed over the weekend that Amgen had made an offer to acquire Onyx for $120 per share, a 38.2% premium above Friday's close.
Amgen, Inc. (AMGN), Onyx Pharmaceuticals, Inc. (ONXX): Is This Biopharmaceutical Stock Still a Buy?
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) has recently experienced a significant jump of nearly 51.3% in only one trading day from $86.82 per share to $131.30 per share.
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN): Is This A Good Acquisition For All?
For the second day in a row, the hot topic in the market is the bidding war for Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX). After rejecting Amgen, Inc.
Amgen, Inc. (AMGN), Onyx Pharmaceuticals, Inc. (ONXX): Avoid This Biotech Investment, For Now
Mergers and acquisitions have always been a big part of the biotechnology industry, and the patent cliff has further increased M&A activity.
Onyx Pharmaceuticals, Inc. (ONXX) Bidding Wars: Who Would Be the Best Suitor?
Recently, Amgen, Inc. (NASDAQ:AMGN) made a surprisingly low offer to acquire the pharmaceutical company Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX).
